PHARMARESEARCH BIO (XKON:A217950) - Stock Price, News & Analysis

A217950 Stock Overview

PHARMA RESEARCH BIO Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products worldwide.

About the company

A217950 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Rewards

Risk Analysis

Has not reported any financial data

Does not have a meaningful market cap (₩121B)

PHARMARESEARCH BIO Co., Ltd. Competitors

Biotoxtech

KOSDAQ:A086040

₩86.6b

NanoEntek

KOSDAQ:A039860

₩87.8b

P&K Skin Research Center

KOSDAQ:A347740

₩87.2b

C&R Research

KOSDAQ:A359090

₩111.5b

Price History & Performance

Summary of all time highs, changes and price drops for PHARMARESEARCH BIO
Historical stock prices
Current Share Price	₩29,950.00
52 Week High	₩32,800.00
52 Week Low	₩19,020.00
Beta	0
1 Month Change	0.34%
3 Month Change	49.38%
1 Year Change	47.17%
3 Year Change	61.89%
5 Year Change	96.39%
Change since IPO	53.59%

Recent updates

Shareholder Returns

	A217950	KR Life Sciences	KR Market
7D	0%	3.1%	3.4%
1Y	47.2%	2.9%	7.1%

Return vs Industry: A217950 exceeded the KR Life Sciences industry which returned 2.9% over the past year.

Return vs Market: A217950 exceeded the KR Market which returned 7.1% over the past year.

Price Volatility

Is A217950's price volatile compared to industry and market?
A217950 volatility
A217950 Average Weekly Movement	7.6%
Life Sciences Industry Average Movement	7.4%
Market Average Movement	5.2%
10% most volatile stocks in KR Market	11.8%
10% least volatile stocks in KR Market	2.4%

Stable Share Price: A217950's share price has been volatile over the past 3 months.

Volatility Over Time: A217950's weekly volatility (8%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2009	n/a	n/a	pr-bio.co.kr

PHARMA RESEARCH BIO Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products worldwide. The company offers ReNTox injection for temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients aged between 18 and 65. It is also developing Clostridium Botulinum Toxin type A, which is in Phase I clinical study for indications, including dynamic equinus foot deformity, upper limb spasticity, blepharospasm, etc. The company was formerly known as BIOCND Inc. and changed its name to PHARMA RESEARCH BIO Co., Ltd.

PHARMARESEARCH BIO Co., Ltd. Fundamentals Summary

How do PHARMARESEARCH BIO's earnings and revenue compare to its market cap?
A217950 fundamental statistics
Market cap	₩121.20b
Earnings (TTM)	₩0
Revenue (TTM)	n/a

n/a

P/E Ratio

n/a

P/S Ratio

Is A217950 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A217950 income statement (TTM)
Revenue	₩0
Cost of Revenue	₩0
Gross Profit	₩0
Other Expenses	₩0
Earnings	₩0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did A217950 perform over the long term?

See historical performance and comparison

PHARMARESEARCH BIO XKON:A217950 Stock Report